

Fax Page 1 To:

Thurston County Public Health

Adapted from WA DOH Form 347-102

Attn. Monique Thompson, (833) 418-1916 (Confidential FAX line)
CONFIDENTIAL SEXUALLY TRANSMITTED INFECTION CASE REPORT
Report STIs within 3 work days (WAC 246-101-101/301)

PATIENT INFORMATION														
LAST NAME I			FIRST NAM			MIDDLE NAM	1E	DAT	E OF BIR	ТН				
					<u>.</u>				мо		DAY		YR	
ADDRESS (Unhoused or	unstably housed i	n the past	3 months)	CITY					STATE		ZIP CODI	E	
TELEPHONE		EMAIL		ENG	LISH SPEAK	KING	i? 🗌 Yes 🗌 No	o *instruction pg. 3	is on D	IAGNOS	S DA	ATE		
()				Pref	erred Lang)	MO DAY YR				YR	
SEX ASSIGNED	GENDER IDENT		1 =	THNICITY			RACE CATEGOI White	RY (check a	ll that a	apply)*:		*Ins	tructions on page 3	
AT BIRTH ☐ Male	AT BIRTH			I —			tina/o/x			☐ Other				
☐ IMale ☐ Female	☐ Transgende ☐ Other	I .	⊒ Non-⊓isp ⊒ Unknown			☐ American In					Unkno	own		
☐ Intersex	☐ Nonbinary / Genderquee			☐ Refused		<u> </u>			/ Other Pacific Islander ☐ Refused					
Refused							EXTENDED RA		··					
CURRENTLY PREGNANT?		XAM (check one):	GENDER OF SEX PARTNERS								//AIDS	Case Report	CURRENTLY ON PrEP?	
Yes	☐ Exposed to II					_	nder FTM 📗 New HI		vious positive w HIV diagnosis at this visit* gative HIV test at this visit No					
□ No		n (No Symptoms)	1 —	☐ Oth	_									
☐ Unk. ☐ NA		(110 0)	1	derqueer	☐ Unk		/n	☐ Did not test (unknown status) ☐ NA						
DIAGNOSIS - D														
GONORRHEA (la		1							/PHILI		Ţ.			
DIAGNOSIS (che ☐ Asymptomatic	•	SITES (all that a		TREATMENT (check all prescril ☐ Ceftriaxone: ☐ 250 mg			-	STAGE (check one): Primary (Chancre, etc.)						
Symptomatic,		Urethra		Ceftriaxon		_	☐ 500 mg ☐ 1 g ☐ 800 mg		Secor	ndary (Ras	sh, et	tc.)		
☐ Pelvic Inflamn		☐ Urine			⁄cin: □1g	3	☐ 2 g	□ 2 g ⊔E		☐ Early Latent (< 1 year)				
☐ Ophthalmia ☐ Disseminated	I	Pharynx		☐ Doxycycline: ☐ 100 mg BID x 7 days					☐ Unknown Duration or Late ☐ Congenital					
Other Compli		□ Pharynx □ Vagina		☐ Gentamicin: ☐ 240 mg ☐ Gemifloxacin: ☐ 320 mg										
		☐ Ocular		Other:					MANIFESTATIONS (check all that apply):					
Date Tested:		Other:	——	Date Prescril	oed:				☐ Neurologic ☐ Otic ☐ Ocular ☐ Tertiary					
CHLAMYDIA (la	b confirmed)							Т	REATI	/IENT (ch	eck o	one):		
DIAGNOSIS (che	-	SITES (all that a			(check all prescribed):			cillin L	A: 🔲 2					
☐ Asymptomati☐ Symptomatic		└ □ Cervix └ □ Urethra		☐ Azithromycin: ☐ 1 g ☐ Doxycycline: ☐ 100 mg BID x 7 days				☐ 2.4 MU IM x 3						
Pelvic Inflam		Urine		Levofloxacin: 500 mg dail						Doxycycline: 100 mg BID x 14 days 100 mg BID x 28 days				
Ophthalmia		☐ Rectum		Other:										
Other Compli	☐ Pharynx ☐ Vagina	İ					Benzathine ☐ 50,000 units/kg IM x 1 PCN-G: ☐ 50,000 units/kg IM x 3							
		☐ Vagina						A	queou	s 🗇 ·	18-24	4 MU/day	IV	
Date Tested:		☐ Other:	:	Date Prescri	bed:				rystalli	ne t		0-14 days		
HERPES SIMPLE					ER DISEASI	ES			enicillii					
DIAGNOSIS		LABORATORY CO	NFIRMATI	1 🗆 🤇	hancroid	nguin	valo.	0	ther: _					
☐ Genital (initial infection only) ☐ Yes ☐ Neonatal ☐ No				☐ Granuloma Inguinale ☐ Lymphogranuloma Venereum				D	ate Pr	escribed:				
PARTNER TREA	ATMENT PLAN	(check one or m	nore optic	ons)										
Providers should manage partner treatment by either treating partners in-person or by prescribing medication for patients to give to their sex partners (see side 2 for additional information).														
for additional information). In-person evaluation - Number of partners treated following medical evaluation:														
Patient-delivered treatment* - Number of partners for whom provider prescribed or provided expedited partner therapy (EPT) medication pack to be delivered by the patient to their partner(s): *Patient-delivered treatment is not recommended for men who have sex with men or patients with syphilis														
REPORTING CLINIC INFORMATION														
DATE	FACILITY NAME DIAGNOSING CLINICIAN													
ADDRESS					CITY				STATE		Z	IP .		
PERSON COMPLETING FORM				TELEPHO))NE)			EMAII	-					

PARTNER MANAGEMENT PLAN INSTRUCTIONS

Gonorrhea or Chlamydia Infection: Partner Treatment

All partners should be treated as if they are infected.

The Washington State Department of Health strongly encourages providers to take responsibility to ensure partner treatment for heterosexuals, by examining and treating all patient's sex partners from the previous 60 days.

If an examination is not possible, providers should offer medication for all sex partners whom patients are able to contact.

Thurston County Public Health may be able to provide free medication to your patient to give their partner(s), if resources permit. Please contact your local health jurisdiction to report cases and inquire about partner management resources, possibly including EPT medications.

Thurston County Public Health recommends you refer all **MSM patients** and **all patients with syphilis or newly diagnosed HIV** to the health department for help notifying partners to ensure that partners receive medication; the opportunity to test for HIV, syphilis, gonorrhea, and chlamydia; and evaluation for HIV Pre-Exposure Prophylaxis (PrEP). Please inform the patient that the health department will contact them to assist with partner notification.

Although the Health Department requests that you refer patients with these risks to us, we also ask that you make every effort to help patients assure that their partners are treated.

Complete the partner management plan on the Confidential Sexually Transmitted Infection Case Report FAX form to define a partner management plan.

For copies of this case report or questions on how to fill it out, call the Thurston County Public Health: (360) 867-2642.

Other STIs: Partner Treatment

All patients with infectious syphilis, chancroid, LGV, or granuloma inguinale are routinely contacted by public health staff. Patients diagnosed with genital herpes should be advised to notify their sex partners and should be informed that their partners should contact their provider for testing. Per CDC treatment guidelines, sex partners of patients who are diagnosed with early syphilis (primary, secondary, or early latent) and may be incubating disease should be treated regardless of test results. Alternative treatment for penicillin allergy among non-pregnant patients, such as an appropriate dosage of doxycycline, can also be found in the guidelines.

RECOMMENDED REGIMENS FOR ANTIMICROBIALS LISTED ON REPORTS*

GONORRHEA -- Uncomplicated

Ceftriaxone 500 mg IM as a single dose for persons weighing < 150 kg (330 lbs), or 1 g IM as a single dose for persons weighing > 150 kg (330 lbs) †

Alternatives for uncomplicated infections of the cervix, urethra, or rectum:

Gentamicin 240 mg IM as a single dose PLUS azithromycin 2 g PO as a single dose $\bf OR$ Cefixime 800 mg orally as a single dose †

- † If treating with ceftriaxone or cefixime, and chlamydia infection has not been excluded, providers should treat for chlamydia with doxycycline 100 mg PO BID for 7 days. During pregnancy, azithromycin 1 g PO as a single dose is recommended to treat chlamydia.
- [‡] Ceftriaxone is the only recommended treatment for pharyngeal gonorrhea. Consult an infectious disease provider or other STI expert for assistance if alternative treatment is required.

CHLAMYDIA -- Uncomplicated

Doxycycline 100 mg PO BID for 7 days **OR** Azithromycin 1g PO as a single dose

Alternatives:

Erythromycin (base) 500 mg PO QID for 7 days OR

Ethylsuccinate 800 mg PO QID for 7 days OR

Ofloxacin 300 mg PO BID for 7 days OR

Levofloxacin 500 mg PO for 7 days

SYPHILIS -- PRIMARY, SECONDARY, OR EARLY LATENT (<1 YEAR)

Benzathine penicillin G 2.4 million units IM in a single dose

SYPHILIS -- LATE OR UNKNOWN DURATION

Benzathine penicillin G 2.4 million units IM for 3 doses at 1 week intervals

DOH 347-102, updated 1/24/2024. For persons with disabilities, this document is available on request in other formats. To submit a request, please call 1-800-525-0127 (TDD/TTY 1-800-833-6388).

^{*} Refer to "STD Diagnostic and Treatment Guidelines" or the Centers for Disease Control and Prevention's (CDC's) website (https://www.cdc.gov/std/treatment/default.htm) for further information on treating pregnant patients, infections of the pharynx, patients with allergies, treatment of infants, and other details.

List of Preferred Languages:

Instructions: Complete the *Preferred Language* section if the patient's preferred language is <u>not</u> English. Patient's preferred language shall be identified by the patient and reported using one of the below categories.

Language Identity Codes:

(L01) Amharic	(L18) Karen	(L35) Sign languages
(L02) Arabic	(L19) Khmer/Cambodian	(L36) Somali
(LO3) Balochi/Baluchi	(L20) Kinyarwanda	(L37) Spanish/Castilian
(L04) Burmese	(L21) Korean	(L38) Swahili/Kiswahili
(L05) Cantonese	(L22) Kosraean	(L39) Tagalog
(L06) Chinese (unspecified)	(L23) Lao	(L40) Tamil
(L07) Chamorro	(L24) Mandarin	(L41) Telugu
(L08) Chuukese	(L25) Marshallese	(L42) Thai
(L09) Dari	(L26) Mixteco	(L43) Tigrinya
(L10) Farsi/Persian	(L27) Nepali	(L44) Ukrainian
(L11) Fijian	(L28) Oromo	(L45) Urdu
(L12) Filipino/Pilipino	(L29) Panjabi/Punjabi	(L46) Vietnamese
(L13) French	(L30) Pashto	(L77) Other language
(L14) German	(L31) Portuguese	(L88) Patient declined to respond
(L15) Hindi	(L32) Romanian/Rumanian	(L99) Unknown

(116) Hmong (133) Russian

(L16) Hmong (L33) Russian (L17) Japanese (L34) Samoan

Race Category and Identity Instructions:

Instructions: The patient's race may either be reported in the general *Race Category* section or the *Extended Race* section on page 1 of the case report. When completing the *Extended Race* section, please report using the codes provided in the list below. If the patient self-identifies as more than one race, each race code shall be reported within the *extended race* section. **Unknown** race can be documented within either one of the race sections.

(R63) Thai

Extended Race Codes:

(R21) Ethiopian

(R01) Afghan	(R22) Fijian	(R43) Mexican/Mexican American	(R64) Tongan
(R02) Afro-Caribbean	(R23) Filipino	(R44) Middle Eastern	(R65) Ugandan
(R03) Alaska Native	(R24) First Nations	(R45) Mien	(R66) Ukrainian
(R04) American Indian	(R25) Guamanian or Chamorro	(R46) Moroccan	(R67) Vietnamese
(R05) Arab	(R26) Hmong/Mong	(R47) Native Hawaiian	(R68) White
(R06) Asian	(R27) Indigenous-Latina/o/x	(R48) Nepalese	(R69) Yemeni
(R07) Asian Indian	(R28) Indonesian	(R49) North African	(R77) Other race
(R08) Bamar/Burman/Burmese	(R29) Iranian	(R50) Oromo	(R99) Unknown
(R09) Bangladeshi	(R30) Iraqi	(R51) Pacific Islander	
(R10) Bhutanese	(R31) Japanese	(R52) Pakistani	
(R11) Black or African American	(R32) Jordanian	(R53) Puerto Rican	
(R12) Central American	(R33) Karen	(R54) Romanian/Rumanian	
(R13) Cham	(R34) Kenyan	(R55) Russian	
(R14) Chicana/o or Chicanx	(R35) Khmer/Cambodian	(R56) Samoan	
(R15) Chinese	(R36) Korean	(R57) Saudi Arabian	
(R16) Congolese	(R37) Kuwaiti	(R58) Somali	
(R17) Cuban	(R38) Lao	(R59) South African	
(R18) Dominican	(R39) Lebanese	(R60) South American	
(R19) Egyptian	(R40) Malaysian	(R61) Syrian	
(R20) Eritrean	(R41) Marshallese	(R62) Taiwanese	

(R42) Mestizo